ZymoGenetics, Inc. today announced that the company has initiated a Phase 1 safety and pharmacokinetic study of PEG-Interferon lambda in healthy volunteers. The Phase 1 study is part of a clinical development program designed to evaluate PEG-Interferon lambda as a potential treatment for patients with hepatitis C and other viral diseases.
From: biz.yahoo.com
ZymoGenetics Begins Clinical Trial for PEG-Interferon lambda as Potential Treatment for Viral Infection
Posted by Ruslan Abuzant at 5:54 AM
Subscribe to:
Post Comments (Atom)
0 comments:
Post a Comment